What is Staar Surg's earnings per share (EPS)?

Staar Surg (STAA) reported diluted earnings per share of $-1.62 for fiscal year 2026. This represents a -295.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Staar Surg Financials

STAA

Source SEC Filings (10-K/10-Q) Updated Jan 2, 2026 Currency USD FYE January

This page shows Staar Surg (STAA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.43x

For every $1 of reported earnings, Staar Surg generates $0.43 in operating cash flow (-$34.2M OCF vs -$80.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$239.4M

YoY-23.7%

5Y CAGR+9.8%

10Y CAGR+12.7%

Staar Surg generated $239.4M in revenue in fiscal year 2026. This represents a decrease of 23.7% from the prior year.

EBITDA

-$83.4M

YoY-1396.4%

Staar Surg's EBITDA was -$83.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1396.4% from the prior year.

Net Income

-$80.4M

YoY-298.1%

Staar Surg reported -$80.4M in net income in fiscal year 2026. This represents a decrease of 298.1% from the prior year.

EPS (Diluted)

$-1.62

YoY-295.1%

Staar Surg earned $-1.62 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 295.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$40.0M

YoY-422.2%

Staar Surg generated -$40.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 422.2% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

50M

YoY+0.4%

5Y CAGR+1.9%

Staar Surg had 50M shares outstanding in fiscal year 2026. This represents an increase of 0.4% from the prior year.

Margins & Returns

Gross Margin

76.2%

YoY-0.1pp

5Y CAGR+1.7pp

10Y CAGR+6.5pp

Staar Surg's gross margin was 76.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.

Operating Margin

-38.3%

YoY-34.3pp

5Y CAGR-46.2pp

10Y CAGR-39.3pp

Staar Surg's operating margin was -38.3% in fiscal year 2026, reflecting core business profitability. This is down 34.3 percentage points from the prior year.

Net Margin

-33.6%

YoY-27.2pp

5Y CAGR-43.0pp

10Y CAGR-34.2pp

Staar Surg's net profit margin was -33.6% in fiscal year 2026, showing the share of revenue converted to profit. This is down 27.2 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$40.1M

YoY-11.6%

5Y CAGR+9.6%

10Y CAGR+19.6%

Staar Surg invested $40.1M in research and development in fiscal year 2026. This represents a decrease of 11.6% from the prior year.

Share Buybacks

$6.5M

Staar Surg spent $6.5M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$5.8M

YoY-75.1%

5Y CAGR-10.4%

10Y CAGR+5.4%

Staar Surg invested $5.8M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 75.1% from the prior year.

STAA Income Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Revenue	$239.4M-23.7%	$313.9M-2.6%	$322.4M+34.7%	$239.4M+3.9%	$230.5M+53.5%	$150.2M
Cost of Revenue	$57.0M-23.3%	$74.3M+6.5%	$69.8M+14.4%	$61.0M+17.7%	$51.8M+35.6%	$38.2M
Gross Profit	$182.4M-23.9%	$239.6M-5.2%	$252.7M+13.1%	$223.4M+25.0%	$178.6M+59.6%	$112.0M
R&D Expenses	$40.1M-11.6%	$45.3M+12.0%	$40.5M+12.5%	$36.0M+6.3%	$33.9M+33.9%	$25.3M
SG&A Expenses	$274.1M+8.7%	$252.2M+12.3%	$224.6M+25.0%	$179.6M+23.6%	$145.3M+45.1%	$100.1M
Operating Income	-$91.7M-627.2%	-$12.6M-144.9%	$28.1M-35.9%	$43.8M+31.4%	$33.3M+181.3%	$11.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$1.8M-116.3%	$11.2M-9.7%	$12.3M+109.8%	$5.9M+55.2%	$3.8M+471.1%	-$1.0M
Net Income	-$80.4M-298.1%	-$20.2M-194.7%	$21.3M-46.2%	$39.7M+44.2%	$27.5M+95.8%	$14.0M
EPS (Diluted)	$-1.62-295.1%	$-0.41-195.3%	$0.43-46.3%	$0.80+42.9%	$0.56+86.7%	$0.30

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$57.8M-39.0%	$94.7M+113.7%	$44.3M+4.1%	$42.6M-13.0%	$49.0M-44.7%	$88.6M-10.5%	$99.0M+28.0%	$77.4M
Cost of Revenue	$14.1M-16.6%	$16.9M+46.3%	$11.5M-21.0%	$14.6M-15.7%	$17.3M-13.9%	$20.1M-2.4%	$20.6M+26.2%	$16.3M
Gross Profit	$43.7M-43.8%	$77.9M+137.4%	$32.8M+17.1%	$28.0M-11.5%	$31.6M-53.8%	$68.5M-12.7%	$78.4M+28.5%	$61.0M
R&D Expenses	$6.9M-24.9%	$9.2M-10.3%	$10.3M-24.9%	$13.7M+74.7%	$7.8M-36.1%	$12.2M+3.2%	$11.9M-11.3%	$13.4M
SG&A Expenses	$66.6M+12.1%	$59.4M-5.4%	$62.8M-26.5%	$85.4M+43.4%	$59.6M-5.2%	$62.8M-5.6%	$66.5M+5.1%	$63.3M
Operating Income	-$22.8M-223.5%	$18.5M+161.7%	-$30.0M+47.8%	-$57.4M-105.7%	-$27.9M-591.2%	$5.7M-52.2%	$11.9M+621.6%	-$2.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$2.3M-123.7%	$9.9M+208.8%	-$9.1M-3210.2%	-$275K-107.1%	$3.9M+22.5%	$3.2M+7.6%	$3.0M+162.0%	$1.1M
Net Income	-$18.3M-306.1%	$8.9M+152.8%	-$16.8M+69.0%	-$54.2M-58.4%	-$34.2M-443.0%	$10.0M+35.2%	$7.4M+321.0%	-$3.3M
EPS (Diluted)	N/A	$0.18+152.9%	$-0.34+69.1%	$-1.10	N/A	$0.20+33.3%	$0.15+314.3%	$-0.07

STAA Balance Sheet

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$509.5M+4.3%	$488.7M+16.7%	$418.8M+21.1%	$345.8M+67.2%	$206.8M
Current Assets	N/A	$367.9M+0.7%	$365.3M+17.2%	$311.7M+14.9%	$271.4M+57.7%	$172.1M
Cash & Equivalents	N/A	$144.2M-21.2%	$183.0M+111.7%	$86.5M-56.7%	$199.7M+80.2%	$110.9M
Inventory	N/A	$26.7M+15.4%	$23.1M+69.8%	$13.6M+30.7%	$10.4M-15.3%	$12.3M
Accounts Receivable	N/A	$77.9M-17.7%	$94.7M+51.7%	$62.4M+43.5%	$43.5M+26.2%	$34.5M
Goodwill	N/A	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M
Total Liabilities	N/A	$112.2M+9.2%	$102.7M+24.2%	$82.7M-5.2%	$87.2M+108.6%	$41.8M
Current Liabilities	N/A	$70.3M+8.1%	$65.0M+25.8%	$51.7M+6.0%	$48.8M+63.2%	$29.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$397.3M+2.9%	$386.0M+14.8%	$336.1M+28.5%	$261.6M+58.6%	$165.0M
Retained Earnings	N/A	-$67.6M-42.7%	-$47.4M+31.1%	-$68.7M+36.6%	-$108.4M+23.6%	-$141.9M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$451.7M-1.0%	$456.4M+4.2%	$437.8M-4.3%	$457.4M-10.2%	$509.5M-5.2%	$537.6M+4.8%	$512.7M+4.1%	$492.5M
Current Assets	$311.5M-3.0%	$321.2M+9.7%	$292.8M-10.3%	$326.5M-11.3%	$367.9M-7.3%	$397.1M+3.5%	$383.8M+4.9%	$365.7M
Cash & Equivalents	$153.2M-13.1%	$176.2M+5.4%	$167.1M-3.5%	$173.1M+20.1%	$144.2M-12.1%	$164.0M-14.9%	$192.8M-13.9%	$224.0M
Inventory	$39.7M+13.7%	$34.9M+1.5%	$34.4M+14.5%	$30.0M+12.4%	$26.7M+11.8%	$23.9M-4.5%	$25.0M-2.4%	$25.6M
Accounts Receivable	$50.1M-16.7%	$60.1M+74.5%	$34.4M-13.8%	$39.9M-48.7%	$77.9M-25.5%	$104.5M+11.4%	$93.8M+45.2%	$64.6M
Goodwill	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M0.0%	$1.8M
Total Liabilities	$107.5M+4.8%	$102.6M+1.4%	$101.2M-5.8%	$107.4M-4.3%	$112.2M+2.5%	$109.5M+5.6%	$103.6M+3.9%	$99.7M
Current Liabilities	$68.5M+11.1%	$61.6M+4.1%	$59.2M-13.4%	$68.4M-2.8%	$70.3M+6.0%	$66.3M+0.3%	$66.2M+5.6%	$62.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$344.2M-2.7%	$353.8M+5.1%	$336.6M-3.8%	$350.0M-11.9%	$397.3M-7.2%	$428.1M+4.6%	$409.1M+4.2%	$392.8M
Retained Earnings	-$148.0M-14.1%	-$129.7M+6.4%	-$138.6M-13.8%	-$121.8M-80.2%	-$67.6M-102.6%	-$33.3M+23.0%	-$43.3M+14.6%	-$50.7M

STAA Cash Flow Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$34.2M-317.7%	$15.7M+7.7%	$14.6M-59.1%	$35.7M-18.8%	$44.0M+70.4%	$25.8M
Capital Expenditures	$5.8M-75.1%	$23.4M+28.6%	$18.2M+0.4%	$18.1M+32.7%	$13.6M+35.2%	$10.1M
Free Cash Flow	-$40.0M-422.2%	-$7.7M-113.4%	-$3.6M-120.4%	$17.6M-41.9%	$30.3M+93.1%	$15.7M
Investing Cash Flow	$46.3M+178.3%	-$59.2M-179.6%	$74.3M+147.5%	-$156.4M-1046.0%	-$13.6M-34.1%	-$10.2M
Financing Cash Flow	-$4.6M-179.6%	$5.7M-22.8%	$7.4M-10.6%	$8.3M-53.4%	$17.8M+11841.6%	$149K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$6.5M	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$3.9M-246.8%	$2.7M+109.8%	-$27.2M-375.2%	-$5.7M-993.1%	$642K-83.2%	$3.8M+136.6%	-$10.4M-148.0%	$21.7M
Capital Expenditures	$1.7M+89.9%	$883K-50.7%	$1.8M+22.1%	$1.5M-74.4%	$5.7M-8.1%	$6.2M-0.1%	$6.2M+19.9%	$5.2M
Free Cash Flow	-$5.6M-413.4%	$1.8M+106.1%	-$29.0M-303.2%	-$7.2M-41.7%	-$5.1M-110.5%	-$2.4M+85.5%	-$16.6M-201.0%	$16.5M
Investing Cash Flow	-$19.4M-467.5%	$5.3M-79.0%	$25.1M-28.9%	$35.4M+281.3%	-$19.5M+44.7%	-$35.2M-70.5%	-$20.7M-227.7%	$16.2M
Financing Cash Flow	-$50K-105.1%	$983K+121.7%	-$4.5M-378.9%	-$948K-761.8%	-$110K-106.8%	$1.6M+890.8%	$163K-96.0%	$4.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$2.0M	N/A	N/A	N/A	N/A	N/A	N/A

STAA Financial Ratios

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Gross Margin	76.2%-0.1pp	76.3%-2.0pp	78.4%-14.9pp	93.3%+15.8pp	77.5%+3.0pp	74.5%
Operating Margin	-38.3%-34.3pp	-4.0%-12.7pp	8.7%-9.6pp	18.3%+3.8pp	14.5%+6.6pp	7.9%
Net Margin	-33.6%-27.2pp	-6.4%-13.1pp	6.6%-9.9pp	16.6%+4.6pp	11.9%+2.6pp	9.3%
Return on Equity	N/A	-5.1%-10.6pp	5.5%-6.3pp	11.8%+1.3pp	10.5%+2.0pp	8.5%
Return on Assets	N/A	-4.0%-8.3pp	4.4%-5.1pp	9.5%+1.5pp	8.0%+1.2pp	6.8%
Current Ratio	N/A	5.23-0.4	5.62-0.4	6.03+0.5	5.56-0.2	5.75
Debt-to-Equity	N/A	0.28+0.0	0.27+0.0	0.25-0.1	0.33+0.1	0.25
FCF Margin	-16.7%-14.3pp	-2.4%-1.3pp	-1.1%-8.5pp	7.3%-5.8pp	13.2%+2.7pp	10.4%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	75.7%-6.5pp	82.2%+8.2pp	74.0%+8.2pp	65.8%+1.1pp	64.6%-12.7pp	77.3%-1.9pp	79.2%+0.3pp	78.9%
Operating Margin	-39.5%-59.0pp	19.5%+87.1pp	-67.6%+67.2pp	-134.8%-77.8pp	-57.0%-63.4pp	6.4%-5.6pp	12.0%+15.0pp	-2.9%
Net Margin	-31.7%-41.1pp	9.4%+47.3pp	-37.9%+89.4pp	-127.3%-57.4pp	-69.9%-81.2pp	11.3%+3.8pp	7.4%+11.8pp	-4.3%
Return on Equity	-5.3%-7.8pp	2.5%+7.5pp	-5.0%+10.5pp	-15.5%-6.9pp	-8.6%-10.9pp	2.3%+0.5pp	1.8%+2.6pp	-0.9%
Return on Assets	-4.0%-6.0pp	1.9%+5.8pp	-3.8%+8.0pp	-11.8%-5.1pp	-6.7%-8.6pp	1.9%+0.4pp	1.4%+2.1pp	-0.7%
Current Ratio	4.55-0.7	5.21+0.3	4.94+0.2	4.78-0.5	5.23-0.8	5.99+0.2	5.80-0.0	5.84
Debt-to-Equity	0.31+0.0	0.29-0.0	0.300.0	0.31+0.0	0.28+0.0	0.260.0	0.250.0	0.25
FCF Margin	-9.7%-11.5pp	1.9%+67.4pp	-65.5%-48.6pp	-16.9%-6.5pp	-10.4%-7.6pp	-2.7%+14.1pp	-16.8%-38.1pp	21.3%

Similar Companies

Biolife Solutions Inc BLFS

$942.3M

Azenta Inc AZTA

$1.0B

Atricure ATRC

$1.4B

ANBIO BIOTECHNOLOGY NNNN

$1.1B

KESTRA MED TECHNOLOGIES LTD KMTS

$1.2B

Frequently Asked Questions

What is Staar Surg's annual revenue?

Staar Surg (STAA) reported $239.4M in total revenue for fiscal year 2026. This represents a -23.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Staar Surg's revenue growing?

Staar Surg (STAA) revenue declined by 23.7% year-over-year, from $313.9M to $239.4M in fiscal year 2026.

Is Staar Surg profitable?

No, Staar Surg (STAA) reported a net income of -$80.4M in fiscal year 2026, with a net profit margin of -33.6%.

What is Staar Surg's EBITDA?

Staar Surg (STAA) had EBITDA of -$83.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Staar Surg's gross margin?

Staar Surg (STAA) had a gross margin of 76.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Staar Surg's operating margin?

Staar Surg (STAA) had an operating margin of -38.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Staar Surg's net profit margin?

Staar Surg (STAA) had a net profit margin of -33.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Staar Surg's free cash flow?

Staar Surg (STAA) generated -$40.0M in free cash flow during fiscal year 2026. This represents a -422.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Staar Surg's operating cash flow?

Staar Surg (STAA) generated -$34.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Staar Surg's capital expenditures?

Staar Surg (STAA) invested $5.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Staar Surg spend on research and development?

Staar Surg (STAA) invested $40.1M in research and development during fiscal year 2026.

Does Staar Surg buy back shares?

Yes, Staar Surg (STAA) spent $6.5M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Staar Surg have outstanding?

Staar Surg (STAA) had 50M shares outstanding as of fiscal year 2026.

Are Staar Surg's earnings high quality?

Staar Surg (STAA) has an earnings quality ratio of 0.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.